Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.

Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophil-induced organ damage. In the WHO classification of myeloid and lymphoid neoplasms, eosinophilic disorders characterized by dysregulated tyrosine kinase (TK) fusion genes are recognized as a new category termed, myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1 or with PCM1-JAK2. In addition to these aforementioned TK fusion genes, rearrangements involving FLT3 and ABL1 genes have also been described. These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN-Eo and a FLT3 or ABL1 rearrangement.

[1]  Sheridan M. Hoy.  Pemigatinib: First Approval , 2020, Drugs.

[2]  M. Nassiri,et al.  Myeloid neoplasm with a novel cryptic PDGFRB rearrangement detected by next-generation sequencing. , 2020, Cancer genetics.

[3]  T. Haferlach,et al.  Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes , 2020, American journal of hematology.

[4]  Sohita Dhillon.  Avapritinib: First Approval , 2020, Drugs.

[5]  S. Verstovsek,et al.  Systematic use of fluorescence in‐situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms , 2020, Histopathology.

[6]  T. Haferlach,et al.  Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. , 2020, Blood advances.

[7]  B. Johansson,et al.  Frequent false‐negative FIP1L1‐PDGFRA FISH analyses of bone marrow samples from clonal eosinophilia at diagnosis , 2019, British journal of haematology.

[8]  M. Triggiani,et al.  Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry , 2019, Leukemia.

[9]  E. Barragán,et al.  RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib , 2019, Acta Haematologica.

[10]  A. Srinivasan,et al.  Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up. , 2019, Journal of pediatric hematology/oncology.

[11]  N. Nakamura,et al.  Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangement , 2019, Bone Marrow Transplantation.

[12]  B. Pitel,et al.  Cryptic ETV6–PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm , 2018, Leukemia & lymphoma.

[13]  B. Bain,et al.  Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia , 2018, Leukemia.

[14]  A. Mead,et al.  Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1) , 2018, Blood.

[15]  V. Najfeld,et al.  Myeloid/lymphoid neoplasms with FGFR1 rearrangement , 2018, Leukemia & lymphoma.

[16]  E. Lippert,et al.  Molecular monitoring of patients with ETV6‐PDGFRB rearrangement: Implications for therapeutic adaptation , 2018, British journal of haematology.

[17]  C. Pui,et al.  PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. , 2018, Blood.

[18]  T. Haferlach,et al.  Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2 , 2018, Haematologica.

[19]  S. Fujiwara,et al.  Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement , 2018, Hematology.

[20]  Seungwoo Hwang,et al.  Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing , 2017, PloS one.

[21]  K. Roskin,et al.  A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. , 2017, Cancer genetics.

[22]  J. Gotlib.  Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis. , 2017, Hematology/oncology clinics of North America.

[23]  W. Tapper,et al.  Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia , 2017, Leukemia.

[24]  K. Döhner,et al.  Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase , 2017, Annals of Hematology.

[25]  A. Bagg,et al.  Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome , 2017, Haematologica.

[26]  A. Reiter,et al.  Myeloid neoplasms with eosinophilia. , 2017, Blood.

[27]  B. Petit,et al.  A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3? , 2016, Leukemia.

[28]  Daniel Boyer.  Blood and Bone Marrow Evaluation for Eosinophilia. , 2016, Archives of pathology & laboratory medicine.

[29]  Joanna L. Conant,et al.  Myeloid Neoplasms with t(5;12) and ETV6-ACSL6 Gene Fusion, Potential Mimickers of Myeloid Neoplasm with PDGFRB Rearrangement: Case Report with Imatinib Therapy and Review of the Literature , 2016, Case reports in medicine.

[30]  M. Loh,et al.  Characterization of leukemias with ETV6-ABL1 fusion , 2015, Haematologica.

[31]  P. Cin,et al.  Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified , 2016, Modern Pathology.

[32]  Dong Chen,et al.  BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. , 2016, Cancer genetics.

[33]  Bing Li,et al.  Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China , 2016, Oncotarget.

[34]  A. Tefferi,et al.  Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing , 2016, Leukemia.

[35]  J. Zehnder,et al.  Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia , 2016, Leukemia.

[36]  A. Tefferi,et al.  Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis , 2016, American journal of hematology.

[37]  A. Tefferi,et al.  Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1‐PDGFRA mutation , 2016, American journal of hematology.

[38]  R. Lifton,et al.  Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. , 2016, Blood.

[39]  W. Hofmann,et al.  Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes , 2015 .

[40]  L. Medeiros,et al.  Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. , 2015, American journal of clinical pathology.

[41]  M. Cazzola,et al.  Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene , 2015, Annals of Hematology.

[42]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[43]  K. Zeng,et al.  Newly identified phenotypes in a FIP1L1/PDGFRA‐associated paediatric HES patient: thrombocytosis, mHPA, young stroke and blindness , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[44]  W. Tapper,et al.  Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes , 2015, Annals of Hematology.

[45]  R. Luthra,et al.  ETV6–FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant , 2014, Leukemia.

[46]  B. Bain,et al.  Should myeloid and lymphoid neoplasms with PCM1‐JAK2 and other rearrangements of JAK2 be recognized as specific entities? , 2014, British journal of haematology.

[47]  R. Aguiar,et al.  Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. , 2014, Blood.

[48]  A. Porwit,et al.  ETV6/FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia , 2014, Journal of Hematopathology.

[49]  J. Gotlib.  World Health Organization‐defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management , 2014, American journal of hematology.

[50]  G. Helbig,et al.  Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1‐PDGFRA‐mutated hypereosinophilic syndrome , 2014, American journal of hematology.

[51]  E. Giugliano,et al.  FIP1L1-PDGFR&agr;-Positive Hypereosinophilic Syndrome in Childhood: A Case Report and Review of Literature , 2014, Journal of pediatric hematology/oncology.

[52]  K. Chonabayashi,et al.  Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia , 2014, Annals of Hematology.

[53]  J. Cayuela,et al.  The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia , 2013, Medicine.

[54]  M. Hudoba,et al.  Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia , 2013, Leukemia & lymphoma.

[55]  M. Cazzola,et al.  Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  W. Hofmann,et al.  Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase , 2013, Leukemia.

[57]  T. Haferlach,et al.  Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1 , 2013, Annals of Hematology.

[58]  C. Dunphy,et al.  Diagnostic complexities of eosinophilia. , 2013, Archives of pathology & laboratory medicine.

[59]  Andrew Chase,et al.  Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome , 2013, Haematologica.

[60]  T. Haferlach,et al.  ICON: Eosinophil Disorders , 2012, The World Allergy Organization journal.

[61]  A. Tefferi,et al.  Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome , 2012, Leukemia.

[62]  T. Haferlach,et al.  Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. , 2012, The Journal of allergy and clinical immunology.

[63]  N. Gutiérrez,et al.  Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement , 2012, European journal of haematology.

[64]  M. Debiec‐Rychter,et al.  Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases , 2012, Leukemia.

[65]  Torsten Haferlach,et al.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field , 2012, Expert review of hematology.

[66]  W. Hofmann,et al.  Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation , 2012, Leukemia.

[67]  T. Haferlach,et al.  Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. , 2011, Blood.

[68]  Philipp Erben,et al.  Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. , 2011, Blood.

[69]  F. Lo‐Coco,et al.  Molecular characterization of paediatric idiopathic hypereosinophilia , 2010, British journal of haematology.

[70]  I. Seferyńska,et al.  Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1‐PDGFRA fusion transcript—results of Polish multicentre study , 2010, Hematological oncology.

[71]  Martin C. Müller,et al.  Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis , 2010, Haematologica.

[72]  L. Medeiros,et al.  8p11 myeloproliferative syndrome: a review. , 2010, Human pathology.

[73]  M. Majewski,et al.  T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome , 2009, Haematologica.

[74]  R. Yeh,et al.  The molecular anatomy of the FIP1L1-PDGFRA fusion gene , 2009, Leukemia.

[75]  A. Jones,et al.  Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions , 2009, Leukemia.

[76]  S. Schnittger,et al.  Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study , 2008, British journal of haematology.

[77]  J. Cools,et al.  Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias , 2008, Leukemia.

[78]  John Kuriyan,et al.  Activation of tyrosine kinases by mutation of the gatekeeper threonine , 2008, Nature Structural &Molecular Biology.

[79]  R. Ravazzolo,et al.  A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. , 2008, Cancer genetics and cytogenetics.

[80]  M. Majewski,et al.  A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1‐PDGFRA‐expressing patients , 2008, British journal of haematology.

[81]  N. Russell,et al.  A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. , 2007, Experimental hematology.

[82]  M. Baccarani,et al.  The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study , 2007, Haematologica.

[83]  O. Haas,et al.  Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. , 2007, The Journal of allergy and clinical immunology.

[84]  M. Rondoni,et al.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2007, Blood.

[85]  N. Schmitz,et al.  Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma , 2007, Leukemia.

[86]  J. Melo,et al.  Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. , 2007, Blood.

[87]  A. Tefferi,et al.  FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. , 2006, Leukemia research.

[88]  Y. Sakaki,et al.  FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation , 2006, Leukemia.

[89]  P. Marynen,et al.  Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant , 2006 .

[90]  D. Gilliland,et al.  Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. , 2006, Methods in molecular medicine.

[91]  P. Brousset,et al.  The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene , 2005, Oncogene.

[92]  S. Bohlander,et al.  A BCR–JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia , 2005, Genes, chromosomes & cancer.

[93]  D. Birnbaum,et al.  PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation , 2005, Leukemia.

[94]  H. F. Barker,et al.  The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. , 2005, Cancer research.

[95]  C. Peschel,et al.  Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia , 2005, Leukemia.

[96]  D. Fabbro,et al.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[97]  D. Metcalfe,et al.  Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. , 2004, Blood.

[98]  N. Cross,et al.  Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. , 2004, Haematologica.

[99]  D. Gilliland,et al.  CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. , 2003, Blood.

[100]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[101]  B. Bain,et al.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.

[102]  M. Fiegl,et al.  Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease , 2002, International Archives of Allergy and Immunology.

[103]  D. Birnbaum,et al.  FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). , 2000, Blood.

[104]  D. Birnbaum,et al.  The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. , 1999, Blood.

[105]  T. Hudson,et al.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome , 1998, Nature Genetics.

[106]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.